The UK and US have reached a important commercial pact that will ensure no duties on British medicine products going into the American market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has committed to increase spending on medicines through the National Health Service (NHS). This commitment guarantees that duties on these key exports will remain at zero for a period of three years.
This deal comes after recent threats to hike tariffs on branded pharmaceutical imports, with figures discussed as high as 100%.
"This deal between the Britain bolsters the worldwide climate for innovative medicines and introduces long-overdue fairness to American-British medicine commerce," a statement said.
Trade Significance
Drugs are one of the Britain's largest goods shipped to the United States, which is by far the largest market for large UK drugmakers.
Statistics show that in the one-year period to the end of last September, the UK exported drugs worth £11.1bn to the US. This value made up nearly one-fifth of British export trade in that span.
"This guarantee safeguards jobs, stimulates investment and paves the way for the UK to emerge as a international leader for medical research," a government official remarked.
Key NHS Changes
The agreement includes several specific commitments from the British government:
- Revised Affordability Limit: The UK will increase the price threshold at which it judges new medicines to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a aim to increase overall public funding on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Payback Limit: The percentage pharmaceutical firms must refund to the NHS to prevent overspending will be limited at fifteen percent. Last year, rebates topped 20%.
Industry Background
This agreement comes amid a ongoing row between the sector and the ministers over medicine costs and NHS adoption.
This friction were intensified by arguments that American customers were paying significantly more for the same drugs than people in the UK and Europe.
Recently, several large drug company projects in the UK have been paused or scrapped, while major investments have been directed toward American operations.
A senior figure stated that the NHS must increase expenditure on medicines, noting that its expenditure on drugs had decreased as a percentage of its total funding over the last ten years.
